(MENAFN- PR Newswire) DUBLIN, Dec. 18, 2023 /PRNewswire/ -- Theravance Biopharma, Inc.
("Theravance Biopharma" or the "Company") (NASDAQ: TBPH ) today announced that members of its management team including Rick E Winningham, CEO, and Aziz Sawaf, CFO, will hold investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024, in San Francisco, CA.
To request a one-on-one meeting with the Theravance Biopharma management team, please contact us at [email protected] .
About Theravance Biopharma
Theravance Biopharma, Inc.'s
focus is to deliver
Medicines that Make a Difference®
in people's lives. In pursuit of its purpose,
Theravance Biopharma
leverages decades of expertise, which has led to the development of FDA-approved YUPELRI®
(revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension, has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in multiple symptom atrophy patients. The Company is committed to creating/driving shareholder value.
For more information, please visit
.
THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo are registered trademarks of the
Theravance Biopharma
group of companies (in the
U.S.
and certain other countries).
YUPELRI®
is a registered trademark of
Mylan Specialty L.P., a
Viatris company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.
Contact:
[email protected]
650-808-4045
SOURCE Theravance Biopharma, Inc.
MENAFN18122023003732001241ID1107617276
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.